Attached files

file filename
EX-99.2 - EXHIBIT 99.2 - OMEGA PROTEIN CORPex99-2.htm
EX-99.1 - EXHIBIT 99.1 - OMEGA PROTEIN CORPex99-1.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

 

Form 8-K

 

 

 

Current Report Pursuant to Section 13 or 15(d) of
the Securities Act of 1934

 

 

 

Date of Report (Date of earliest event reported): June 7, 2016

 

 

 

Omega Protein Corporation
(Exact name of registrant as specified in its charter)

 

 

 

Nevada
(State or other jurisdiction
of incorporation)

 

001-14003
(Commission
File Number)

76-0562134
(I.R.S. Employer
Identification No.)

 

 

2105 City West Blvd., Suite 500

Houston, Texas
(Address of principal executive offices)

77042
(Zip Code)

 

(713) 623-0060
(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[ ]     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[ ]     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[ ]     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14-2(b))

 

[ ]     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CRF 240.133-4(c))

 

 

 
 

 

 

Item 8.01 Other Events

 

On June 7, 2016, Omega Protein Corporation (the “Company”) posted on its website at www.omegaprotein.com a presentation regarding the Company and its pending proxy contest against Wynnefield Partners Small Cap Value, L.P. and its affiliates (“Wynnefield”) and a supplemental slide to the presentation regarding the lawsuit filed by Wynnefield. Copies of the presentation and the supplemental slide to the presentation are included as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and are incorporated into this Item 8.01 by reference.

 

Item 9.01 Financial Statements, Pro Forma Financial Information and Exhibits

 

 

 

(a)

Exhibits.

 

 

99.1

Omega Protein Corporation Presentation dated June 2016.

  99.2 Supplemental Slide dated June 6, 2016.

 

 
 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

Omega Protein Corporation

 

 

 

 

Dated:     June 7, 2016   

                    /s/ John D. Held                                 

 

John D. Held

Executive Vice President and General Counsel